Testing IC14 for ARDS on a ventilator
Part of Lungs & breathing clinical trials.
This trial tests a new treatment called IC14 for people in the hospital on a breathing machine for ARDS (a severe lung injury). The study aims to see if IC14, which blocks a protein involved in inflammation, can help the lungs heal faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are on a breathing machine (ventilator) and have been diagnosed with ARDS (a severe lung injury) within the last 48 hours.
- You do not have severe pre-existing organ failure, such as needing home oxygen, severe heart failure, or kidney dialysis.
- You have not taken strong immune-suppressing drugs (like Enbrel, Humira, or Actemra) in the last 30 days.
- You are not pregnant or breastfeeding.
- You are not receiving only comfort (palliative) care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.
This pilot study tests NOA-001, a treatment given to people with ARDS (a serious lung condition) who are already on a breathing machine. It looks at whether the treatment can improve outcomes in ARDS caused by either non-COVID illnesses or COVID-19.
This study looks at a specific breathing event (“avalanche phenomenon”) when the lungs are opened in people with early, moderate-to-severe ARDS. The goal is to understand what’s happening in the lungs and whether it can guide better care.
This trial tests a more tailored way to set the amount of air delivered by a ventilator in people with severe ARDS. The goal is to see if personalized breathing settings can improve breathing and heart-related monitoring while patients are in intensive care.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.